<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-111104</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">With so much attention paid to adenosine diphosphate receptor blockers, is there still a role for aspirin resistance?</dc:title>
<dc:description xml:lang="en">No disponible</dc:description>
<dc:creator>Picó, Francisco</dc:creator>
<dc:creator>Villegas, Manuel</dc:creator>
<dc:creator>Consuegra Sánchez, Luciano</dc:creator>
<dc:creator>Fernández Bergés, Daniel</dc:creator>
<dc:creator>Dau, Derek</dc:creator>
<dc:creator>Jaulent, Leticia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">No disponible</dc:description>
<dc:source>Rev Esp Cardiol;66(4): 311-312, abr. 2013. tab, ilus</dc:source>
<dc:identifier>ibc-111104</dc:identifier>
<dc:title xml:lang="es">Cuando la resistencia a los bloqueadores del receptor de adenosindifosfato centra toda la atención, ¿la resistencia a la aspirina tiene algo que decir?</dc:title>
<dc:subject>^d254^s22073</dc:subject>
<dc:subject>^d28614</dc:subject>
<dc:subject>^d24885^s22066</dc:subject>
<dc:subject>^d52438</dc:subject>
<dc:subject>^d29638</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29310</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22965</dc:subject>
<dc:subject>^d52881^s22074</dc:subject>
<dc:subject>^d28606</dc:subject>
<dc:subject>^d27951^s22073</dc:subject>
<dc:subject>^d254^s22079</dc:subject>
<dc:subject>^d254^s22044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201304</dc:date>
</metadata>
</record>
</ibecs-document>
